Yun Zhong
Stock Analyst at Wedbush
(0.58)
# 3,817
Out of 4,734 analysts
26
Total ratings
30.43%
Success rate
-15.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PASG Passage Bio | Assumes: Outperform | $4 | $0.62 | +548.30% | 2 | Nov 29, 2024 | |
| MLTX MoonLake Immunotherapeutics | Assumes: Outperform | $92 → $73 | $45.82 | +59.32% | 1 | Nov 5, 2024 | |
| RZLT Rezolute | Initiates: Outperform | $12 | $4.92 | +143.90% | 1 | Nov 5, 2024 | |
| PTGX Protagonist Therapeutics | Initiates: Outperform | $58 | $38.10 | +52.23% | 1 | Nov 5, 2024 | |
| AVXL Anavex Life Sciences | Maintains: Buy | $35 → $28 | $9.85 | +184.26% | 2 | Feb 9, 2023 | |
| TSHA Taysha Gene Therapies | Downgrades: Neutral | n/a | $1.53 | - | 2 | Feb 2, 2023 | |
| FOLD Amicus Therapeutics | Maintains: Buy | $14 → $16 | $9.51 | +68.24% | 1 | Jan 18, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $125 → $160 | $116.79 | +37.00% | 11 | Dec 22, 2022 | |
| RCKT Rocket Pharmaceuticals | Initiates: Buy | $35 | $10.16 | +244.49% | 1 | Nov 1, 2022 | |
| BLUE bluebird bio | Downgrades: Hold | $700 | $8.14 | +8,499.51% | 2 | Jul 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $14.91 | +208.52% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.99 | +234.45% | 1 | May 5, 2021 |
Passage Bio
Nov 29, 2024
Assumes: Outperform
Price Target: $4
Current: $0.62
Upside: +548.30%
MoonLake Immunotherapeutics
Nov 5, 2024
Assumes: Outperform
Price Target: $92 → $73
Current: $45.82
Upside: +59.32%
Rezolute
Nov 5, 2024
Initiates: Outperform
Price Target: $12
Current: $4.92
Upside: +143.90%
Protagonist Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $58
Current: $38.10
Upside: +52.23%
Anavex Life Sciences
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $9.85
Upside: +184.26%
Taysha Gene Therapies
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.53
Upside: -
Amicus Therapeutics
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $9.51
Upside: +68.24%
Sarepta Therapeutics
Dec 22, 2022
Maintains: Buy
Price Target: $125 → $160
Current: $116.79
Upside: +37.00%
Rocket Pharmaceuticals
Nov 1, 2022
Initiates: Buy
Price Target: $35
Current: $10.16
Upside: +244.49%
bluebird bio
Jul 1, 2021
Downgrades: Hold
Price Target: $700
Current: $8.14
Upside: +8,499.51%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $14.91
Upside: +208.52%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $2.99
Upside: +234.45%